Psychosocial impact of irritable bowel syndrome: A brief review

Ballou, Sarah; Bedell, Alyse; Keefer, Laurie

doi:10.4291/wjgp.v6.i4.120

Cited by 30 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides gastrointestinal symptoms, about 70% of IBS patients also suffer from psychological problems, especially emotional disorders (Garakani et al, 2003). IBS has been shown to be a risk factor for-and a strong correlate of-severe mental health disorders and is associated with a marked decrease in the quality of life (Ballou, Bedell, & Keefer, 2015). Moreover, IBS involves high societal costs (Canavan, West, & Card, 2014), likely due to ineffective treatments as well as work absenteeism.…”

Section: Introductionmentioning

confidence: 99%

Exposure-based cognitive behavioral therapy for irritable bowel syndrome. A single-case experimental design across 13 subjects

Boersma

Ljótsson

Edebol-Carlman

et al. 2016

Cognitive Behaviour Therapy

View full text Add to dashboard Cite

2016): Exposure-based cognitive behavioral therapy for irritable bowel syndrome. A single-case experimental design across 13 subjects, Cognitive Behaviour Therapy, ABSTRACT Irritable bowel syndrome (IBS) is a highly prevalent disorder with a significant impact on quality of life. The presence of psychological symptoms in IBS patients such as catastrophic worry and behavioral avoidance suggests the possible efficacy of cognitive behavioral interventions. Exposure-based cognitive behavioral therapy (CBT) has proven to be a promising approach but has only been investigated in a few studies and mainly via the Internet. Therefore, the aims of this study were to extend and replicate previous findings and to evaluate whether an individual, face-to-face, exposure-based CBT leads to improvement in gastrointestinal symptoms, pain catastrophizing, avoidance behavior and quality of life in IBS patients. Thirteen patients with IBS according to Rome III criteria participated in a single-case experimental study using a five-week baseline and a subsequent twelve-session intervention phase focusing on psycho-education, mindfulness and in vivo exposure. Standardized measurement of gastrointestinal symptoms, pain catastrophizing, avoidance behavior and quality of life was conducted weekly during baseline as well as intervention phase and at six-month follow-up. Results showed that over 70% of patients improved significantly on gastrointestinal symptoms, pain catastrophizing, and quality of life. Effects on avoidance behavior were modest. These results strengthen and extend earlier findings and provide further support for the efficacy of exposure-based strategies for IBS.

show abstract

Section: Introductionmentioning

confidence: 99%

Exposure-based cognitive behavioral therapy for irritable bowel syndrome. A single-case experimental design across 13 subjects

Boersma

Ljótsson

Edebol-Carlman

et al. 2016

Cognitive Behaviour Therapy

View full text Add to dashboard Cite

show abstract

“…[2][3][4] Three main IBS subtypes are recognised, determined by stool consistency pattern: IBS with diarrhoea (IBS-D), IBS with constipation (IBS-C) and IBS with mixed constipation and diarrhoea (IBS-M). 2 IBS significantly impacts on health-related quality of life (QoL) 5 and is a substantial socioeconomic burden due to the high healthcare costs, lost work days and reduced productivity 6,7 associated with the condition.…”

Section: Introductionmentioning

confidence: 99%

Randomised clinical trial: exploratory phase 2 study of ONO‐2952 in diarrhoea‐predominant irritable bowel syndrome

Duffy

Sharpe

Nabata

et al. 2016

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackground ONO‐2952 is a novel and selective inhibitor of translocator protein 18 kDa that reduces stress‐induced defecation and visceral hyperalgesia in rat models.AimTo evaluate the efficacy and safety of ONO‐2952 in females with irritable bowel syndrome with diarrhoea in an exploratory proof‐of‐concept study.MethodsA randomised, double‐blind, placebo‐controlled study was conducted at 49 US centres. Two hundred subjects with irritable bowel syndrome with diarrhoea (Rome III criteria) were randomised to ONO‐2952 20 mg, or 60 mg, or placebo. Subjects recorded irritable bowel syndrome symptoms daily during a 2‐week baseline period, the 4‐week treatment period and for 4 weeks post‐treatment. The co‐primary endpoints were change from baseline to week 4 in abdominal pain, stool consistency and stool frequency.ResultsImprovements in irritable bowel syndrome symptoms were seen with ONO‐2952 over placebo in per‐protocol analyses for all three co‐primary endpoints, but these did not reach statistical significance at the 5% level. The largest improvement was seen with ONO‐2952 60 mg. ONO‐2952 was well tolerated with a safety profile similar to that of placebo. Most adverse events were mild or moderate in severity and not treatment related.Conclusion ONO‐2952 showed evidence of clinical efficacy in reducing irritable bowel syndrome‐related symptoms in female subjects with irritable bowel syndrome with diarrhoea, and further evaluation is, therefore, warranted to assess its potential as a treatment for irritable bowel syndrome with diarrhoea (NCT01844180).

show abstract

“…While this paper focuses mainly on unconscious mechanisms underlying the relationship between GM and psychological outcomes (such as interoceptive processes and neurotransmitter production), it is acknowledged that conscious mechanisms also have potential psychological implications. For example, gastrointestinal symptoms can be noticeably unpleasant and, particularly in IBS sufferers, can lead to impairment in daily functioning (Ballou, Bedell, & Keefer, 2015), anxiety and depression (Roohafza et al, 2016), avoidance behaviors (Van Oudenhove et al, 2016), and poor quality of life (Canavan, West, & Card, 2015). Conscious mechanisms can also lead to positive psychological outcomes as exemplified by patients following gastric bypass surgery.…”

Section: Behaviormentioning

confidence: 99%

The role of the brain–gut–microbiota axis in psychology: The importance of considering gut microbiota in the development, perpetuation, and treatment of psychological disorders

Ganci

Suleyman

Butt³

et al. 2019

Brain and Behavior

View full text Add to dashboard Cite

IntroductionThe prevalence of psychological disorders remains stable despite steady increases in pharmacological treatments suggesting the need for auxiliary treatment options. Consideration of the brain–gut–microbiota axis (BGMA) has made inroads into reconceptualizing psychological illness from a more holistic perspective. While our understanding of the precise role of gut microbiota (GM) in psychological illness is in its infancy, it represents an attractive target for novel interventions.MethodAn extensive review of relevant literature was undertaken.ResultsGut microbiota are proposed to directly and indirectly influence mood, cognition, and behavior which are key components of mental health. This paper outlines how GM may be implicated in psychological disorders from etiology through to treatment and prevention using the Four P model of case formulation.ConclusionMoving forward, integration of GM into the conceptualization and treatment of psychological illness will require the discipline of psychology to undergo a significant paradigm shift. While the importance of the GM in psychological well‐being must be respected, it is not proposed to be a panacea, but instead, an additional arm to a multidisciplinary approach to treatment and prevention.

show abstract

Psychosocial impact of irritable bowel syndrome: A brief review

Cited by 30 publications

References 29 publications

Exposure-based cognitive behavioral therapy for irritable bowel syndrome. A single-case experimental design across 13 subjects

Exposure-based cognitive behavioral therapy for irritable bowel syndrome. A single-case experimental design across 13 subjects

Randomised clinical trial: exploratory phase 2 study of ONO‐2952 in diarrhoea‐predominant irritable bowel syndrome

The role of the brain–gut–microbiota axis in psychology: The importance of considering gut microbiota in the development, perpetuation, and treatment of psychological disorders

Contact Info

Product

Resources

About